Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' SAVEN A' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 63 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Andrey, J; Saven, A
      Therapeutic advances in the treatment of hairy cell leukemia

      LEUKEMIA RESEARCH
    2. Saven, A
      Treatment of hairy-cell leukemia

      NEW ENGLAND JOURNAL OF MEDICINE
    3. Felding-Habermann, B; O'Toole, TE; Smith, JW; Fransvea, E; Ruggeri, ZM; Ginsberg, MH; Hughes, PE; Pampori, N; Shattil, SJ; Saven, A; Mueller, BM
      Integrin activation controls metastasis in human breast cancer

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    4. Glaspy, J; Jadeja, JS; Justice, G; Kessler, J; Richards, D; Schwartzberg, L; Rigas, J; Kuter, D; Harmon, D; Prow, D; Demetri, G; Gordon, D; Arseneau, J; Saven, A; Hynes, H; Boccia, R; O'Byrne, J; Colowick, AB
      A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy

      BRITISH JOURNAL OF CANCER
    5. Smith, RE; Jaiyesimi, IA; Meza, LA; Tchekmedyian, N; Chan, D; Griffith, H; Brosman, S; Bukowski, R; Murdock, M; Rarick, M; Saven, A; Colowick, AB; Fleishman, A; Gayko, U; Glaspy, J
      Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer

      BRITISH JOURNAL OF CANCER
    6. Tetreault, SA; Saven, A
      Delayed onset of autoimmune hemolytic anemia complicating cladribine therapy for Waldenstrom macroglobulinemia

      LEUKEMIA & LYMPHOMA
    7. Duchini, A; Younossi, ZM; Saven, A; Bordin, GM; Knowles, HJ; Pockros, PJ
      An open-label pilot trial of cladibrine (2-chlorodeoxyadenosine) in patients with primary sclerosing cholangitis

      JOURNAL OF CLINICAL GASTROENTEROLOGY
    8. Tetreault, SA; Robbins, BA; Saven, A
      Treatment of hairy cell leukemia-variant with cladribine

      LEUKEMIA & LYMPHOMA
    9. Piro, LD; White, CA; Grillo-Lopez, AJ; Janakiraman, N; Saven, A; Beck, TM; Varns, C; Shuey, S; Czuczman, M; Lynch, JW; Kolitz, JE; Jain, V
      Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed orrefractory low-grade or follicular non-Hodgkin's lymphoma

      ANNALS OF ONCOLOGY
    10. Saven, A; Burian, C; Adusumalli, J; Koziol, JA
      Filgrastim for cladribine-induced neutropenic fever in patients with hairycell leukemia

      BLOOD
    11. Saven, A; Burian, C
      Cladribine activity in adult Langerhans-cell histiocytosis

      BLOOD
    12. Pauls, JD; Brems, J; Pockros, PJ; Saven, A; Wagner, RL; Weber, R; Metcalfe, D; Christiansen, SC
      Mastocytosis - Diverse presentations and outcomes

      ARCHIVES OF INTERNAL MEDICINE
    13. TETREAULT S; ABLER SL; ROBBINS B; SAVEN A
      PERIPHERAL T-CELL LYMPHOMA AFTER ANTI-CD20 ANTIBODY THERAPY

      Journal of clinical oncology
    14. PAULS JD; BREMS J; POCKROS PJ; SAVEN A; WAGNER RL; WEBER R; METCALFE DD; CHRISTIANSEN SC
      MASTOCYTOSIS - DIVERSE PRESENTATIONS AND OUTCOMES

      Journal of allergy and clinical immunology
    15. Liu, ES; Burian, C; Miller, WE; Saven, A
      Bolus administration of cladribine in the treatment of Waldenstrom macroglobulinaemia

      BRITISH JOURNAL OF HAEMATOLOGY
    16. SAVEN A; BURIAN C; KOZIOL JA; PIRO LD
      LONG-TERM FOLLOW-UP OF PATIENTS WITH HAIRY-CELL LEUKEMIA AFTER CLADRIBINE TREATMENT

      Blood
    17. GOLLARD R; MILLER WE; PIRO LD; SAVEN A
      2-CHLORODEOXYADENOSINE ADMINISTRATION TO PATIENTS WITH THE MYELOID BLAST PHASE OF CHRONIC MYELOGENOUS LEUKEMIA

      Leukemia & lymphoma
    18. WHITE CA; GRILLOLOPEZ AJ; MALONEY D; BODKIN D; CZUCZMAN M; MCLAUGHLIN P; CABANILLAS F; SAVEN A; SALEH M
      REVIEW OF SINGLE-AGENT IDEC-C2B8 SAFETY AND EFFICACY RESULTS IN LOW-GRADE OR FOLLICULAR NON-HODGKINS-LYMPHOMA (NHL)

      European journal of cancer
    19. MEISENBERG BR; MILLER WE; MCMILLAN R; CALLAGHAN M; SLOAN C; BREHM T; KOSTY MP; KROENER J; LONGMIRE R; SAVEN A; PIRO LD
      OUTPATIENT HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL RESCUE FOR HEMATOLOGIC AND NONHEMATOLOGIC MALIGNANCIES

      Journal of clinical oncology
    20. SAVEN A; LEE T; SCHLUTZ M; JACOBS A; ELLISON D; LONGMIRE R; PIRO L
      MAJOR ACTIVITY OF CLADRIBINE IN PATIENTS WITH DE-NOVO B-CELL PROLYMPHOCYTIC LEUKEMIA

      Journal of clinical oncology
    21. SAVEN A
      PURINE ANALOGS FOR TREATMENT OF REFRACTORY ESSENTIAL MIXED CRYOGLOBULINEMIA - RESPONSE

      Mayo Clinic proceedings
    22. WEBER R; MARTINEZ D; COLWELL C; WALKER R; BYLUND D; GRIFFIN J; SAVEN A
      ACTIVATED PROTEIN-C RESISTANCE IN PATIENTS WITH VENOUS THROMBOEMBOLISM FOLLOWING TOTAL JOINT REPLACEMENT

      Blood
    23. RAJA N; MILLER WE; MCMILLAN R; KOSTY MP; SAVEN A; MEISENBERG BR; MASON JR
      TANDEM CYCLES OF HIGH-DOSE CHEMOTHERAPY (HDC) WITH PERIPHERAL-BLOOD PROGENITOR-CELL RESCUE (PBPCR) FOR PATIENTS WITH RELAPSED OR HIGH-RISK LYMPHOMA

      Blood
    24. LIU E; BURIAN C; MILLER W; SAVEN A
      BOLUS ADMINISTRATION OF CLADRIBINE IN THE TREATMENT OF WALDENSTROM MACROGLOBULINEMIA (WM)

      Blood
    25. SAVEN A; BURIAN C; KOZIOL J; PIRO L
      LONG-TERM FOLLOW-UP OF PATIENTS WITH HAIRY-CELL LEUKEMIA (HCL) FOLLOWING CLADRIBINE TREATMENT

      Blood
    26. SAVEN A; PIRO LD
      2-CHLORODEOXYADENOSINE - A POTENT ANTIMETABOLITE WITH MAJOR ACTIVITY IN THE TREATMENT OF INDOLENT LYMPHOPROLIFERATIVE DISORDERS

      HEMATOLOGY AND CELL THERAPY
    27. GOODMAN MG; SPINOSA JC; SAVEN A; PIRO LD; WORMSLEY S
      NEW PERSPECTIVES ON THE APPROACH TO CHRONIC LYMPHOCYTIC-LEUKEMIA

      Leukemia & lymphoma
    28. SAVEN A; LEE T; KOSTY M; PIRO L
      CLADRIBINE AND MITOXANTRONE DOSE-ESCALATION IN INDOLENT NON-HODGKINS-LYMPHOMA

      Journal of clinical oncology
    29. SAVEN A; CHEUNG WK; SMITH I; MOYER M; JOHANNSEN T; ROSE E; GOLLARD R; KOSTY M; MILLER WE; PIRO LD
      PHARMACOKINETIC STUDY OF ORAL AND BOLUS INTRAVENOUS 2-CHLORODEOXYADENOSINE IN PATIENTS WITH MALIGNANCY

      Journal of clinical oncology
    30. POCKROS PJ; YOUNOSSI ZM; WILKES LB; SAVEN A
      AN OPEN-LABEL PILOT-STUDY OF 2-CHLORODEOXYADENOSINE (2-CDA) IN THE TREATMENT OF EARLY-STAGE PRIMARY SCLEROSING CHOLANGITIS (PSC)

      Hepatology
    31. SAVEN A
      FLUDARABINE TREATMENT AND TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE

      Lancet
    32. SAVEN A
      THE SCRIPPS-CLINIC EXPERIENCE WITH CLADRIBINE (2-CDA) IN THE TREATMENT OF CHRONIC LYMPHOCYTIC-LEUKEMIA

      Seminars in hematology
    33. LEE TC; MILLER WE; CURD JG; PIRO LD; SAVEN A
      PROLONGED, COMPLETE REMISSION AFTER 2-CHLORODEOXYADENOSINE THERAPY INA PATIENT WITH REFRACTORY ESSENTIAL MIXED CRYOGLOBULINEMIA

      Mayo Clinic proceedings
    34. GOLLARD RP; ROBBINS BA; PIRO L; SAVEN A
      ACUTE MYELOGENOUS LEUKEMIA PRESENTING WITH BULKY LYMPHADENOPATHY - CASE-REPORT AND LITERATURE-REVIEW

      Acta haematologica
    35. SAVEN A; LEMON RH; KOSTY M; BEUTLER E; PIRO LD
      2-CHLORODEOXYADENOSINE ACTIVITY IN PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC-LEUKEMIA

      Journal of clinical oncology
    36. GOLLARD R; LEE TC; PIRO LD; SAVEN A
      THE OPTIMAL MANAGEMENT OF HAIRY-CELL LEUKEMIA

      Drugs
    37. SAVEN A; EMANUELE S; KOSTY M; KOZIOL J; ELLISON D; PIRO L
      2-CHLORODEOXYADENOSINE ACTIVITY IN PATIENTS WITH UNTREATED, INDOLENT NON-HODGKINS-LYMPHOMA

      Blood
    38. PIRO LD; PETRONI G; BARCOS M; JOHNSON J; SAVEN A; PETERSON B
      BOLUS INFUSION 2-CHLORODEOXYADENOSINE (2-CDA) AS FIRST-LINE THERAPY OF LOW-GRADE NON-HODGKINS-LYMPHOMA (NHL) - CALGB-9153

      Blood
    39. SAVEN A; LEE T; SCHLUTZ M; LONGMIRE R; PIRO L
      MAJOR ACTIVITY OF 2-CHLORODEOXYADENOSINE (2-CDA) IN DE-NOVO B-CELL PROLYMPHOCYTIC LEUKEMIA (B-PLL)

      Blood
    40. DOUER D; SAVEN A; WATKINS K; GOLLARD R; KAHN A; PIRO L; LEVINE AM
      REMISSION INDUCTION IN NEWLY-DIAGNOSED AML PATIENTS AGED 55-75 YEARS USING A 5 DAY IDARUBICIN SCHEDULE IN COMBINATION WITH CYTARABINE

      Blood
    41. STONE RM; PIRO ID; SAVEN A; BERG DT; BRYAN WJ; FAY JW; HERZIG GP; HERZIG RH; SHIELDS AF; COLEMAN BS; LEE EJ
      A PHASE-I NOVEL ALKYLATING AGENT (AA), ADOZELESIN PATIENTS (PTS) WITHREFRACTORY HEMATOLOGIC MALIGNANCIES (HM)

      Blood
    42. HANSEN DA; ROBBINS BA; BYLUND DJ; ELLISON DJ; PIRO LD; SAVEN A
      BENCE-JONES PROTEINURIA IN CHRONIC LYMPHOCYTIC-LEUKEMIA - REPLY

      American journal of clinical pathology
    43. PIRO LD; ELLISON DJ; SAVEN A
      THE SCRIPPS-CLINIC EXPERIENCE WITH 2-CHLORODEOXYADENOSINE IN THE TREATMENT OF HAIRY-CELL LEUKEMIA

      Leukemia & lymphoma
    44. CARRERA CJ; SAVEN A; PIRO LD
      PURINE METABOLISM OF LYMPHOCYTES - TARGETS FOR CHEMOTHERAPY DRUG DEVELOPMENT

      Hematology/oncology clinics of North America
    45. SAVEN A; PIRO L
      2-CHLORODEOXYADENOSINE THERAPY IN CHRONIC LYMPHOCYTIC-LEUKEMIA

      The New England journal of medicine
    46. SAVEN A; PIRO L
      NEWER PURINE ANALOGS FOR THE TREATMENT OF HAIRY-CELL LEUKEMIA

      The New England journal of medicine
    47. SAVEN A; PIRO LD; LEMON RH; FIGUEROA ML; KOSTY M; ELLISON DJ; BEUTLER E
      COMPLETE HEMATOLOGIC REMISSIONS IN CHRONIC-PHASE, PHILADELPHIA-CHROMOSOME-POSITIVE, CHRONIC MYELOGENOUS LEUKEMIA AFTER 2-CHLORODEOXYADENOSINE

      Cancer
    48. ELLISON DJ; SHARPE RW; ROBBINS BA; SPINOSA JC; LEOPARD JD; SAVEN A; PIRO LD
      IMMUNOMORPHOLOGICAL ANALYSIS OF BONE-MARROW BIOPSIES AFTER TREATMENT WITH 2-CHLORODEOXYADENOSINE FOR HAIRY-CELL LEUKEMIA

      Blood
    49. SAVEN A; FOON KA; PIRO LD
      2-CHLORODEOXYADENOSINE-INDUCED COMPLETE REMISSIONS IN LANGERHANS-CELLHISTIOCYTOSIS

      Annals of internal medicine
    50. SAVEN A; PIRO LD
      2-CHLORODEOXYADENOSINE - A NEWER PURINE ANALOG ACTIVE IN THE TREATMENT OF INDOLENT LYMPHOID MALIGNANCIES

      Annals of internal medicine
    51. SAVEN A; PIRO LD
      CROSS-RESISTANCE TO PURINE ANALOGS IN HAIRY-CELL LEUKEMIA - RESPONSE

      Annals of internal medicine
    52. SAVEN A; PIRO L
      2-CHLORODEOXYADENOSINE TREATMENT IN HAIRY-CELL LEUKEMIA - RESPONSE

      Annals of internal medicine
    53. HANSEN DA; ROBBINS BA; BYLUND DJ; PIRO LD; SAVEN A; ELLISON DJ
      IDENTIFICATION OF MONOCLONAL IMMUNOGLOBULINS AND QUANTITATIVE IMMUNOGLOBULIN ABNORMALITIES IN HAIRY-CELL LEUKEMIA AND CHRONIC LYMPHOCYTIC-LEUKEMIA

      American journal of clinical pathology
    54. SAVEN A; PIRO LD
      2-CHLORODEOXYADENOSINE IN THE TREATMENT OF HAIRY-CELL LEUKEMIA AND CHRONIC LYMPHOCYTIC-LEUKEMIA

      Leukemia & lymphoma
    55. SAVEN A; PIRO LD
      2-CHLORODEOXYADENOSINE IN THE TREATMENT OF HAIRY-CELL LEUKEMIA

      Cancer investigation
    56. SAVEN A
      COMPARATIVE EFFICACY OF THE NEWER NUCLEOSIDES (FLUDARABINE, 2'-DEOXYCOFORMYCIN, AND 2-CHLORODEOXYADENOSINE) IN THE TREATMENT OF INDOLENT LYMPHOID MALIGNANCIES

      Seminars in hematology
    57. SAVEN A; FIGUEROA ML; PIRO LD; ROSENBLATT JD
      2-CHLORODEOXYADENOSINE TO TREAT REFRACTORY HISTIOCYTOSIS-X

      The New England journal of medicine
    58. SAVEN A
      2-CHLORODEOXYADENOSINE FOR PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA RESISTANT TO FLUDARABINE (VOL 328, PG 812, 1993)

      The New England journal of medicine
    59. SAVEN A; PIRO LD
      THE NEWER PURINE ANALOGS - SIGNIFICANT THERAPEUTIC ADVANCE IN THE MANAGEMENT OF LYMPHOID MALIGNANCIES

      Cancer
    60. ROBBINS BA; ELLISON DJ; SPINOSA JC; CAREY CA; LUKES RJ; POPPEMA S; SAVEN A; PIRO LD
      DIAGNOSTIC APPLICATION OF 2-COLOR FLOW-CYTOMETRY IN 161 CASES OF HAIRY-CELL LEUKEMIA

      Blood
    61. SAVEN A; LEMON RH; KOSTY M; BEUTLER E; PIRO LD
      2-CHLORODEOXYADENOSINE (2-CDA) ACTIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL)

      Blood
    62. SAVEN A; PIRO LD
      COMPLETE REMISSIONS IN HAIRY-CELL LEUKEMIA WITH 2-CHLORODEOXYADENOSINE AFTER FAILURE WITH 2'-DEOXYCOFORMYCIN

      Annals of internal medicine
    63. FOON KA; THIRUVENGADAM R; SAVEN A; BERNSTEIN ZP; GALE RP
      GENETIC RELATEDNESS OF LYMPHOID MALIGNANCIES - TRANSFORMATION OF CHRONIC LYMPHOCYTIC-LEUKEMIA AS A MODEL

      Annals of internal medicine


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/08/20 alle ore 15:32:34